BVGH Coordinates Ebola Therapeutic Monoclonal Antibody Project
BVGH is coordinating a collaborative initiative to discover, develop, and deliever fully human, broad spectrum, protective anti-Ebola virus monoclonal antibodies. Theraclone Sciences, Inc., a Seattle-based biotechnology company, will lead the R&D effort and co-manage the project with BVGH. Theraclone will receive up to 4.4 million USD from the Wellcome Trust and other funders for this work. "New collaborative approaches with researchers and clinicians from impacted countries, disease experts, and antibody therapeutic scientists from biotechnology companies are desperately needed to develop new and effective products," said Jennifer Dent, president of BVGH. A press release from Theraclone with further detail is available here. Updated Ebola product pipelines, maintained by BVGH, are available here.
2015 Patents for Humanity Awards for Medicine Given to Sanofi and Novartis
Two WIPO Re:Search members, Sanofi and Novartis, were awarded 2015 Patents for Humanity Awards for their work on expanding development and access of drugs. Novartis provided their entire tuberculosis R&D program to TB Alliance to develop new therapies, especially for drug-resistant forms of the disease. Sanofi, in partnership with PATH, University of Calfornia at Berkeley, and Amyris, Inc., and with funding from the Bill and Melinda Gates Foundation, has developed and is manufacturing synthetic artemisinin anti-malarial compounds. Learn more about Sanofi's development and manufacturing process here. More about the 2015 Patents for Humanity Awards is available here.
Industry, Public Health Organizations, Researchers, and Funders Unite to Advance Ebola R&D
The second issue of the BVGH FundFinder Newsletter focuses on Ebola. This includes a survey of clinical stage vaccine projects that are being advanced aggressively through coordinated efforts involving industry, funding organizations, and public agencies. There is also a profile of a broader Ebola R&D program that includes ten organizations but is funded solely by DARPA. Read the full newsletter here.
WHO Releases New Report on Neglected Tropical Diseases
The World Health Organization (WHO) has released their third report on neglected tropical diseases (NTDs), Investing to Overcome the Global Impact of Neglected Tropical Diseases. The report focuses on the need for domestic investment by countries affected by NTDs, with the objective of first meeting the targets laid out in WHO's Roadmap on NTDs, and second ensuring sustainable, universal health coverage.The progress made to date on increasing access and innovation is also discussed, including a mention of WIPO Re:Search, "Major access agreements have been brokered between companies . . . through the World Intellectual Property Organization's Re:Search Consortium." The full report is available here.
WIPO Re:Search Gains Momentum in the Fight Against Neglected Tropical Diseases, Malaria and Tuberculosis
WIPO Re:Search signed on more than a dozen new members in 2014, including two leading pharmaceutical firms, and nearly doubled the number of research agreements using shared intellectual property to promote the fight against neglected tropical diseases, tuberculosis and malaria. Click here for the full press release from WIPO.